218 related articles for article (PubMed ID: 34708541)
1. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
[TBL] [Abstract][Full Text] [Related]
2. The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
Soppa U; Schumacher J; Florencio Ortiz V; Pasqualon T; Tejedor FJ; Becker W
Cell Cycle; 2014; 13(13):2084-100. PubMed ID: 24806449
[TBL] [Abstract][Full Text] [Related]
3. p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain.
Ding Q; Grammer JR; Nelson MA; Guan JL; Stewart JE; Gladson CL
J Biol Chem; 2005 Feb; 280(8):6802-15. PubMed ID: 15557280
[TBL] [Abstract][Full Text] [Related]
4. Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice.
Masuda T; Itoh K; Higashitsuji H; Higashitsuji H; Nakazawa N; Sakurai T; Liu Y; Tokuchi H; Fujita T; Zhao Y; Nishiyama H; Tanaka T; Fukumoto M; Ikawa M; Okabe M; Fujita J
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10885-90. PubMed ID: 22711815
[TBL] [Abstract][Full Text] [Related]
5. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
[TBL] [Abstract][Full Text] [Related]
6. A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.
Becker W
FEBS J; 2018 Apr; 285(7):1203-1211. PubMed ID: 29193696
[TBL] [Abstract][Full Text] [Related]
7. Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle.
Chen JY; Lin JR; Tsai FC; Meyer T
Mol Cell; 2013 Oct; 52(1):87-100. PubMed ID: 24119401
[TBL] [Abstract][Full Text] [Related]
8. A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21.
Bélanger F; Roussel C; Sawchyn C; St-Hilaire E; Gezzar-Dandashi S; Kimenyi Ishimwe AB; Mallette FA; Wurtele H; Drobetsky E
J Biol Chem; 2023 Jul; 299(7):104900. PubMed ID: 37301510
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Liang YC; Lin-Shiau SY; Chen CF; Lin JK
J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
[TBL] [Abstract][Full Text] [Related]
10. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
Hu J; Deng H; Friedman EA
Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression.
Halfter H; Friedrich M; Resch A; Kullmann M; Stögbauer F; Ringelstein EB; Hengst L
Cancer Res; 2006 Jul; 66(13):6530-9. PubMed ID: 16818624
[TBL] [Abstract][Full Text] [Related]
14. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate.
Zhang X; Min KW; Wimalasena J; Baek SJ
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2051-60. PubMed ID: 22814742
[TBL] [Abstract][Full Text] [Related]
16. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).
Ashford AL; Oxley D; Kettle J; Hudson K; Guichard S; Cook SJ; Lochhead PA
Biochem J; 2014 Jan; 457(1):43-56. PubMed ID: 24134204
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
19. Tetrandrine inhibits deregulated cell cycle in pancreatic cancer cells: Differential regulation of p21
Singh K; Dong Q; TimiriShanmugam PS; Koul S; Koul HK
Cancer Lett; 2018 Jul; 425():164-173. PubMed ID: 29605511
[TBL] [Abstract][Full Text] [Related]
20. Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants.
Ewton DZ; Lee K; Deng X; Lim S; Friedman E
Int J Cancer; 2003 Jan; 103(1):21-8. PubMed ID: 12455049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
